Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Twist Bioscience CorpTWST · Entity 3619 | President and COO | October 02, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Twist Bioscience Corp
Report date October 02, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 185,088 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Sale · Disposed 25,714 · Balance 185,088 F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 04, 2021 Filed Oct 6, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 358 | $8.82 | $3,157.56 |
DisclosureSEC source: 0001214659-21-010285 · marketforms-53982.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 257 | $105.50 | $27,113.50 |
DisclosureSEC source: 0001214659-21-010285 · marketforms-53982.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,566 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 827 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-21-009352 · marketforms-53728.xml · derivative · entry 7 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,513 Underlying: Common Stock · 827 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,517 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-21-009352 · marketforms-53728.xml · derivative · entry 6 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,442 Underlying: Common Stock · 1,517 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 358 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-21-009352 · marketforms-53728.xml · derivative · entry 5 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Stock · 358 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,702 | $117.99 | $318,808.98 |
DisclosureSEC source: 0001214659-21-009352 · marketforms-53728.xml · nonDerivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,823 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 827 | $23.33 | $19,293.91 |
DisclosureSEC source: 0001214659-21-009352 · marketforms-53728.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,517 | $26.66 | $40,443.22 |
DisclosureSEC source: 0001214659-21-009352 · marketforms-53728.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:26 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 358 | $8.82 | $3,157.56 |
DisclosureSEC source: 0001214659-21-009352 · marketforms-53728.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2021 Filed Aug 26, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 91 | $108.26 | $9,851.66 |
DisclosureSEC source: 0001214659-21-009024 · marketforms-53659.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,823 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,027 | $100.49 | $103,203.23 |
DisclosureSEC source: 0001214659-21-008952 · marketforms-53636.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,914 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 827 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-21-008175 · marketforms-53522.xml · derivative · entry 7 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,340 Underlying: Common Stock · 827 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,517 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-21-008175 · marketforms-53522.xml · derivative · entry 6 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,959 Underlying: Common Stock · 1,517 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 358 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-21-008175 · marketforms-53522.xml · derivative · entry 5 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,983 Underlying: Common Stock · 358 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,702 | $117.27 | $316,863.54 |
DisclosureSEC source: 0001214659-21-008175 · marketforms-53522.xml · nonDerivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,850 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 827 | $23.33 | $19,293.91 |
DisclosureSEC source: 0001214659-21-008175 · marketforms-53522.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,517 | $26.66 | $40,443.22 |
DisclosureSEC source: 0001214659-21-008175 · marketforms-53522.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 358 | $8.82 | $3,157.56 |
DisclosureSEC source: 0001214659-21-008175 · marketforms-53522.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 20:32 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 305 | $117.34 | $35,788.70 |
DisclosureSEC source: 0001214659-21-007855 · marketforms-53389.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,850 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 23:27 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 827 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-21-007314 · marketforms-53260.xml · derivative · entry 8 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,167 Underlying: Common Stock · 827 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 23:27 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,517 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-21-007314 · marketforms-53260.xml · derivative · entry 7 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,476 Underlying: Common Stock · 1,517 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 23:27 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 358 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-21-007314 · marketforms-53260.xml · derivative · entry 6 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,341 Underlying: Common Stock · 358 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 23:27 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,702 | $131.70 | $355,853.40 |
DisclosureSEC source: 0001214659-21-007314 · marketforms-53260.xml · nonDerivative · entry 5 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,155 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 23:27 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 827 | $23.33 | $19,293.91 |
DisclosureSEC source: 0001214659-21-007314 · marketforms-53260.xml · nonDerivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 23:27 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,517 | $26.66 | $40,443.22 |
DisclosureSEC source: 0001214659-21-007314 · marketforms-53260.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 23:27 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 358 | $8.82 | $3,157.56 |
DisclosureSEC source: 0001214659-21-007314 · marketforms-53260.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 23:27 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 257 | $131.48 | $33,790.36 |
DisclosureSEC source: 0001214659-21-007314 · marketforms-53260.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,155 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:19 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 827 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-21-006314 · marketforms-53030.xml · derivative · entry 7 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,994 Underlying: Common Stock · 827 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:19 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,517 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-21-006314 · marketforms-53030.xml · derivative · entry 6 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,993 Underlying: Common Stock · 1,517 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:19 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 358 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-21-006314 · marketforms-53030.xml · derivative · entry 5 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,699 Underlying: Common Stock · 358 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:19 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,702 | $104.64 | $282,737.28 |
DisclosureSEC source: 0001214659-21-006314 · marketforms-53030.xml · nonDerivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,412 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:19 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 827 | $23.33 | $19,293.91 |
DisclosureSEC source: 0001214659-21-006314 · marketforms-53030.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:19 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,517 | $26.66 | $40,443.22 |
DisclosureSEC source: 0001214659-21-006314 · marketforms-53030.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:19 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 358 | $8.82 | $3,157.56 |
DisclosureSEC source: 0001214659-21-006314 · marketforms-53030.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2021 Filed May 24, 2021 21:15 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,027 | $97.75 | $100,389.25 |
DisclosureSEC source: 0001214659-21-005864 · marketforms-52893.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,412 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 827 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-21-004989 · marketforms-52676.xml · derivative · entry 7 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,821 Underlying: Common Stock · 827 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,517 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-21-004989 · marketforms-52676.xml · derivative · entry 6 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,510 Underlying: Common Stock · 1,517 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 358 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-21-004989 · marketforms-52676.xml · derivative · entry 5 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,057 Underlying: Common Stock · 358 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,702 | $117.39 | $317,187.78 |
DisclosureSEC source: 0001214659-21-004989 · marketforms-52676.xml · nonDerivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,439 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 827 | $23.33 | $19,293.91 |
DisclosureSEC source: 0001214659-21-004989 · marketforms-52676.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,517 | $26.66 | $40,443.22 |
DisclosureSEC source: 0001214659-21-004989 · marketforms-52676.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 358 | $8.82 | $3,157.56 |
DisclosureSEC source: 0001214659-21-004989 · marketforms-52676.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 21:25 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 305 | $133.12 | $40,601.60 |
DisclosureSEC source: 0001214659-21-004540 · marketforms-52306.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,439 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 22:44 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 827 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001214659-21-004021 · marketforms-52205.xml · derivative · entry 7 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,648 Underlying: Common Stock · 827 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 22:44 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,517 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-21-004021 · marketforms-52205.xml · derivative · entry 6 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,027 Underlying: Common Stock · 1,517 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 22:44 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 358 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-21-004021 · marketforms-52205.xml · derivative · entry 5 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,415 Underlying: Common Stock · 358 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 22:44 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,702 | $126.72 | $342,397.44 |
DisclosureSEC source: 0001214659-21-004021 · marketforms-52205.xml · nonDerivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,744 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 22:44 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 827 | $23.33 | $19,293.91 |
DisclosureSEC source: 0001214659-21-004021 · marketforms-52205.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 22:44 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,517 | $26.66 | $40,443.22 |
DisclosureSEC source: 0001214659-21-004021 · marketforms-52205.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 22:44 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 358 | $8.82 | $3,157.56 |
DisclosureSEC source: 0001214659-21-004021 · marketforms-52205.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.